Comprehensive guide to the most popular research peptides — covering mechanisms of action, research applications, laboratory protocols, and sourcing considerations for BPC-157, Semaglutide, Tirzepatide, AOD9604, and 12+ additional peptides

TL;DR — The Short Answer

The most popular research peptides fall into five functional categories: regenerative/protective peptides (BPC-157, TB-500, GHK-Cu, Epithalon), metabolic peptides (Semaglutide, Tirzepatide, AOD9604, 5-Amino-1MQ, MOTS-c, Retatrutide, Cagrilintide), growth hormone secretagogues (CJC-1295, Ipamorelin), behavioral/sleep peptides (DSIP, Selank, Semax), and telomere-related peptides (Epithalon). Each has distinct mechanisms of action, receptor targets, and research applications.

This guide provides a structured overview of each peptide’s mechanism, typical research dosage ranges, administration routes, stability profiles, and sourcing quality considerations — enabling researchers to make informed decisions about which peptides to include in their studies.

Key Stats at a Glance

Peptide Categories Overview

Research peptides can be grouped by their primary mechanism of action and target receptor systems. Understanding these categories helps researchers select appropriate peptides for their specific experimental questions.

Category 1: Regenerative & Protective Peptides

These peptides are studied for their roles in tissue repair, wound healing, and cellular protection. They typically act through growth factor modulation, angiogenesis stimulation, and anti-inflammatory pathways.

Category 2: Metabolic Peptides — GLP-1/GIP Receptor Agonists

This category has seen explosive growth in research interest. These peptides target the incretin hormone system, which regulates appetite, insulin secretion, and energy metabolism.

Category 3: Metabolic Peptides — Other Mechanisms

Category 4: GHRH/GHS (Growth Hormone Releasing Peptides)

Category 5: Behavioral & Cognitive Peptides

BPC-157 Peptide: Mechanisms, Research Applications & Lab Protocols

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) derived from a protein found in human gastric juice. It was originally identified for its gastroprotective properties and has since been studied for systemic tissue repair effects.

Mechanism of Action

BPC-157’s mechanism is multi-faceted and not fully characterized, but known actions include:

– Angiogenesis stimulation — Upregulates vascular endothelial growth factor (VEGF) and promotes new blood vessel formation

– Growth factor modulation — Increases expression of FGF, EGF, and TGF-β

– Nitric oxide (NO) pathway regulation — Modulates NO synthase activity

– Anti-inflammatory effects — Reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)

– Collagen production — Stimulates type I and type III collagen synthesis

Typical Research Applications

Laboratory Protocol Notes

Reconstitution:

– BPC-157 is highly water-soluble

– Reconstitute in sterile water or bacteriostatic water

– Gentle swirling — do not vortex

– pH stable at 3.0–7.0

Storage:

– Lyophilized: -20°C (stable 2+ years)

– Reconstituted (at 1 mg/mL): -20°C for 3–6 months, aliquot to avoid freeze-thaw

– 4°C: Use within 7 days

Quality considerations:

– BPC-157 is prone to oxidation at cysteine residues

– Request COA with LC-MS to verify [M+H]⁺ = 1419.6 Da

– Purity ≥98% recommended for in vivo research

Semaglutide Peptide GLP-1 Research

What Is Semaglutide?

Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a 31-amino acid incretin hormone. It is structurally modified to resist DPP-4 enzymatic degradation, giving it a long half-life suitable for once-weekly administration in research.

Key Structural Modifications

– Substitution of alanine at position 8 with 2-aminoisobutyric acid (Aib)

– Lysine at position 26 linked to a C18 fatty diacid chain (for albumin binding)

– These modifications extend half-life from ~2 minutes (native GLP-1) to ~7 days

Mechanism of Action

– GLP-1 receptor agonist — Binds to and activates GLP-1 receptors

– Glucose-dependent insulin secretion — Stimulates insulin release only when glucose is elevated

– Glucagon suppression — Reduces glucagon secretion

– Gastric emptying delay — Slows nutrient absorption

– Appetite regulation — Acts on CNS GLP-1 receptors in the hypothalamus

Research Applications

Reconstitution and Stability

Solubility:

– Semaglutide dissolves in sterile water at 0.5–2 mg/mL

– May require gentle heating to 37°C for complete dissolution at higher concentrations

– Avoid vigorous shaking

Stability:

– Lyophilized: -20°C (2+ years)

– Reconstituted at 1 mg/mL: -20°C (3 months), 4°C (1 week)

– Semaglutide is sensitive to temperatures above 40°C for extended periods

Quality verification:

– LC-MS [M+H]⁺ = 4113.6 Da

– Purity ≥98% by HPLC for research use

Tirzepatide: Dual GIP/GLP-1 Research Applications Guide

What Is Tirzepatide?

Tirzepatide is a synthetic 39-amino acid peptide that acts as a dual agonist at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. It is the first approved dual incretin receptor agonist and has generated significant research interest due to its superior weight reduction effects compared to GLP-1 monotherapy.

Mechanism

The GIP component is believed to contribute additional metabolic benefits beyond GLP-1 alone, including direct effects on adipose tissue metabolism and enhanced energy expenditure.

Research Applications

Quality Verification

– LC-MS [M+H]⁺ = 4813.5 Da

– Purity ≥98% for research use

AOD9604: Metabolic Research Peptide Applications

What Is AOD9604?

AOD9604 is a synthetic peptide corresponding to amino acids 177–191 of human growth hormone (HGH). Unlike full-length HGH, AOD9604 has been modified to retain the lipolytic (fat-burning) properties of HGH while eliminating the growth-promoting and diabetogenic effects.

Mechanism

– Binds to the HGH receptor but only activates the JAK/STAT pathway partially

– Stimulates lipolysis (fat breakdown) in adipocytes

– Does NOT stimulate IGF-1 production (unlike full HGH)

– Enhances metabolic rate and fatty acid oxidation

Quality Verification

– LC-MS [M+H]⁺ = 1780.9 Da

– Length: 15 amino acids

– Purity ≥95% standard; ≥98% recommended for research

5-Amino-1MQ: Mechanism of Action in Metabolic Research

What Is 5-Amino-1MQ?

5-Amino-1MQ (5-Amino-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide) is not a peptide but a nucleoside analog that functions as an NNMT (Nicotinamide N-methyltransferase) inhibitor. It is included in this guide because it is commonly studied in the same metabolic research context.

Mechanism

– Inhibits NNMT enzyme activity

– Increases NAD+ levels in cells

– Promotes mitochondrial function and energy expenditure

– Reduces adiposity and improves glucose metabolism in animal models

Research Applications

– Obesity and metabolic syndrome models

– Mitochondrial dysfunction studies

– NAD+ metabolism research

– Energy expenditure regulation

Cagrilintide: Amylin Analog Research Applications

What Is Cagrilintide?

Cagrilintide is a long-acting synthetic analog of amylin, a pancreatic hormone that complements insulin in regulating postprandial glucose. It is being studied in combination with semaglutide (CagriSema) for metabolic research.

Mechanism

– Amylin receptor agonist

– Slows gastric emptying

– Suppresses postprandial glucagon secretion

– Reduces food intake via CNS effects

MOTS-c: Mitochondrial-Derived Peptide Research Guide

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid mitochondrial-derived peptide (MDP) encoded by mitochondrial DNA. It represents a novel class of peptides that act as signaling molecules linking mitochondrial function to whole-body metabolism.

Mechanism

– Regulates nuclear gene expression in response to metabolic stress

– Activates AMPK pathway

– Improves insulin sensitivity

– Enhances fatty acid oxidation

– Protects against age-related metabolic decline

GHK-Cu Peptide: Copper Peptide Research Applications

What Is GHK-Cu?

GHK-Cu (Glycyl-L-histidyl-L-lysine-copper) is a naturally occurring copper-binding tripeptide. It is one of the most studied copper peptides, with research spanning wound healing, skin regeneration, and anti-aging applications.

Mechanism

– Copper transport — Delivers copper to cells for enzymatic reactions

– Gene expression modulation — Upregulates ~4,000 genes, downregulates ~100

– Anti-inflammatory — Reduces IL-1, TNF-α

– Antioxidant — Reduces oxidative stress markers

– Collagen synthesis — Stimulates collagen deposition

Epithalon / Epitalon: Telomere Research Peptide Guide

What Is Epithalon?

Epithalon (also known as Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide complex epithalamin. It is studied primarily for its effects on telomerase activity and circadian rhythm regulation.

Mechanism

– Telomerase activation — Induces telomerase activity in somatic cells

– Pineal function — Restores melatonin production patterns

– Circadian rhythm — Normalizes age-related rhythm disruption

– Antioxidant — Reduces oxidative damage markers

Research Applications

– Telomere length maintenance research

– Circadian rhythm studies

– Age-related pineal decline

– Oxidative stress and aging

DSIP: Delta Sleep-Inducing Peptide Research Applications

What Is DSIP?

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (9 amino acids) first isolated from rabbit brain tissue based on its ability to induce delta (slow-wave) sleep. Beyond sleep regulation, DSIP has been studied for its effects on stress response, pain modulation, and neuroprotection.

Sequence

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Mechanism

– Endogenous sleep regulation via delta wave promotion

– Stress response modulation (HPA axis)

– Melatonin synthesis modulation

– Anti-nociceptive (pain-reducing) effects

Selank & Semax: Anxiolytic and Cognitive Research Peptides

What Are Selank and Semax?

Selank and Semax are synthetic peptides developed from natural regulatory peptides found in the blood of laboratory animals. Both are derived from tuftsin, an immunomodulatory tetrapeptide, but have been modified to enhance stability and specificity for research applications. They are frequently studied alongside nootropics and cognitive enhancers due to their effects on neurotransmitter systems and neurotrophic factors.

Selank Mechanism of Action

Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) that functions primarily through inhibition of enkephalin-degrading enzymes, thereby increasing the half-life of endogenous enkephalins. Key mechanistic actions include:

– Enkephalin catabolism inhibition — Prolongs the action of leu-enkephalin and met-enkephalin in the CNS

– BDNF modulation — Upregulates brain-derived neurotrophic factor expression in the hippocampus and prefrontal cortex

– GABAergic system regulation — Modulates GABA-A receptor subunit expression, contributing to anxiolytic effects

– Serotonin system interaction — Reduces stress-induced serotonin release in limbic structures

– Cytokine balance — Decreases pro-inflammatory cytokines (IL-1β, IL-6) while increasing IL-10

Semax Mechanism of Action

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of ACTH(4–10) fragment with enhanced stability and CNS penetration. Unlike other ACTH fragments, Semax has no hormonal (corticosteroidogenic) activity but retains neurotrophic and cognitive actions:

– BDNF and NGF upregulation — Increases brain-derived neurotrophic factor and nerve growth factor in the hippocampus and cortex

– Dopamine and serotonin modulation — Elevates dopamine levels in the striatum and prefrontal cortex; modulates serotonin turnover

– PKC and MAPK/ERK pathway activation — Triggers intracellular signaling cascades involved in synaptic plasticity and neuroprotection

– Antioxidant defense — Upregulates superoxide dismutase (SOD) and glutathione peroxidase activity

– Cholinergic system potentiation — Enhances acetylcholine release in the hippocampus

Research Applications Comparison

Reconstitution and Research Protocol Notes

Selank:

– Highly water-soluble; reconstitute in sterile saline or water

– Sensitive to proteolysis — use cold chain throughout handling

– Reconstituted at 1 mg/mL: -20°C (<1 month)

– LC-MS [M+H]⁺ = 779.5 Da; purity ≥98% recommended

Semax:

– Soluble in water and saline; pH range 5.0–7.0 preferred

– More stable than Selank due to PG-Pro C-terminus motif

– Reconstituted at 1–5 mg/mL: -20°C (2–3 months)

– LC-MS [M+H]⁺ = 834.4 Da; purity ≥98% for in vivo use

– Intranasal administration is the most common research route for CNS studies

CJC-1295: Growth Hormone Releasing Hormone Research

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It incorporates Drug Affinity Complex (DAC) technology — a chemical modification that binds the peptide to albumin, extending its half-life to approximately 8 days.

Mechanism

– GHRH receptor agonist

– Pulsatile GH release (preserves natural rhythm)

– Increased IGF-1 production

– Anabolic effects mediated through GH/IGF-1 axis

Quality Verification

– LC-MS [M+H]⁺ = 4508.3 Da

– Purity ≥98% for research

– Note: CJC-1295 without DAC (CJC-1295 w/o DAC) has a much shorter half-life (~30 min)

TB-500 (Thymosin Beta-4): Research Applications Review

What Is TB-500?

TB-500 is the synthetic version of Thymosin Beta-4, a naturally occurring 43-amino acid peptide that is the major actin-sequestering molecule in human cells. It plays a central role in cell migration, angiogenesis, and wound healing.

Mechanism

Quality Verification

– LC-MS [M+H]⁺ = 4964.5 Da

– Purity ≥95% for research; ≥98% for in vivo

Retatrutide: Triple Agonist Research Peptide Guide

What Is Retatrutide?

Retatrutide is a synthetic peptide that functions as a triple agonist at the GIP, GLP-1, and glucagon receptors. It represents the latest generation of incretin-based research peptides.

Receptor Activation Profile

Why Triple Agonism Matters for Research

The addition of glucagon receptor agonism distinguishes retatrutide from dual agonists (tirzepatide). Glucagon receptor activation increases energy expenditure — potentially leading to greater weight reduction than GLP-1 alone or GIP/GLP-1 dual agonism.

Quality Verification

– LC-MS [M+H]⁺ = 4782.4 Da (approximate, sequence-dependent)

– Purity ≥98% for research use

Ipamorelin: Growth Hormone Secretagogue Research

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide that acts as a growth hormone secretagogue (GHS). Unlike GHRH analogs (CJC-1295), ipamorelin stimulates GH release through the ghrelin receptor (GHS-R1a).

Mechanism

– GHS-R1a (ghrelin receptor) agonist

– Stimulates pulsatile GH release

– Minimal effect on cortisol, prolactin, or ACTH (more selective than other GHS)

– Does NOT stimulate appetite (unlike ghrelin)

Key Research Characteristics

Peptide Selection Decision Framework: Matching Research Goals to Peptides

Choosing the right peptide for a given research question is not simply a matter of selecting the most popular option. The following framework provides a systematic approach to peptide selection based on research objectives, model systems, and desired endpoints.

Decision Matrix by Research Goal

Selection Workflow

Step 1 — Define your primary research question. Is your study about mechanism (how does a pathway work?) or intervention (does this compound produce an effect?). For mechanistic studies, choose a peptide with a well-characterized receptor target (semaglutide for GLP-1; CJC-1295 for GHRH). For intervention studies, consider peptides with broader, pleiotropic effects (BPC-157).

Step 2 — Consider your animal model and dosing constraints. Mice metabolize peptides differently than rats. Rodents have shorter GLP-1 half-lives than humans — semaglutide may require twice-weekly dosing in mice versus once-weekly in humans. Check published pharmacokinetic data for your specific model before finalizing doses.

Step 3 — Evaluate peptide stability against your experimental timeline. A short-half-life peptide (ipamorelin at ~2 hours) requires multiple daily dosing or osmotic pump implantation. A long-half-life peptide (CJC-1295 DAC at ~8 days) requires fewer interventions but complicates washout periods for crossover designs.

Step 4 — Account for solvent compatibility and administration route. Some peptides precipitate in certain buffers or require specific pH ranges. Verify solubility in your intended vehicle before beginning the study. The administration route directly affects bioavailability (see Administration Routes Comparison section).

Step 5 — Incorporate appropriate controls. Each peptide class requires specific negative controls:

– Vehicle-only control — Essential for every study to control for injection stress and handling

– Receptor antagonist control — Recommended for mechanistic studies (e.g., exendin(9–39) for GLP-1 receptor studies)

– Positive control — A known active comparator (e.g., metformin for metabolic studies, diazepam for anxiolytic studies)

Common Pitfalls in Peptide Selection

– Overlooking species-specific pharmacology: GLP-1 receptor sequences differ between rodents and humans. Semaglutide binds rat GLP-1R with ~10-fold lower affinity than human GLP-1R. Verify cross-reactivity before extrapolating dose-response data.

– Ignoring vehicle effects: Saline is not always biologically inert. Some peptides require PBS (pH 7.4), others prefer acetic acid or DMSO. Test vehicle alone controls rigorously.

– Assuming linear dose-response: BPC-157 shows a U-shaped dose relationship in some wound healing models — lower doses (~200 mcg) may outperform higher doses (~1 mg). Always conduct a preliminary dose-ranging study.

Administration Routes Comparison for Research Animals

Choice of administration route is a critical experimental variable that directly affects peptide bioavailability, pharmacokinetics, and research outcomes. The following comparison covers the four most common routes used in peptide research.

Route Comparison Overview

Detailed Route Characteristics

Subcutaneous (SC):

SC administration is the most common route for peptide research due to its low stress profile and consistent absorption kinetics. Peptides are deposited into the subcutaneous space and absorbed through capillary beds. For metabolic peptides (semaglutide, tirzepatide), SC administration mimics the slow-release profile typical of depot formulations. Absorption rate can be slowed by administering at cooler temperatures or choosing injection sites with less vascularization (scruff versus flank). SC administration of BPC-157 at sites distal to the injury has been shown to produce systemic effects, though local administration near the target tissue may enhance regional bioavailability.

Intraperitoneal (IP):

IP administration delivers peptides directly into the peritoneal cavity, where they are absorbed primarily via the mesenteric vasculature and portal vein. This results in first-pass hepatic metabolism, which can significantly reduce bioavailability of peptides susceptible to liver enzymes. IP is widely used in rodent metabolic research because it is technically straightforward and allows higher injection volumes than SC or IM. However, variability in absorption (due to injection depth, angle relative to organs, and animal movement during injection) can increase data scatter. IP administration is generally not recommended for peptides with narrow therapeutic windows or when precise pharmacokinetic characterization is needed.

Intramuscular (IM):

IM administration is less commonly used in rodent peptide research due to the small muscle mass available. It is more relevant for larger animal models (rabbits, minipigs, dogs). For depot formulations (sustained-release peptide suspensions), IM provides a reservoir effect that prolongs absorption. IM injections must be performed with care to avoid sciatic nerve damage in rodents — the quadriceps (vastus lateralis) is the preferred site in rats. Due to injection stress and volume limitations, IM is typically reserved for peptides with specific depo formulations or when SC/IP routes are contraindicated.

Intranasal (IN):

IN administration has gained significant research interest for CNS-targeted peptide studies because it provides a direct pathway to the brain via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier (BBB). This is particularly relevant for peptides like Selank, Semax, and DSIP, which have CNS targets. Key considerations:

– Olfactory deposition: Particles 10–30 µm in diameter deposit optimally in the nasal cavity; smaller droplets may reach the lungs

– Head position: Supine or reflex head extension during administration improves olfactory region deposition

– Volume control: Volumes exceeding 10 µL per nostril in mice risk drainage into the trachea/lungs rather than CNS

– Systemic spillover: IN administration typically results in only 1–10% systemic bioavailability, so it is unsuitable when peripheral effects are the primary endpoint

Practical Guidance for Route Selection

Administration Schedule Considerations

Dosing frequency should be matched to both the peptide’s half-life and the chosen route:

– Once-weekly peptides (semaglutide, tirzepatide, retatrutide, CJC-1295 DAC): SC only — the slow-release profile requires subcutaneous deposition

– Daily peptides (BPC-157, GHK-Cu, TB-500): SC or IP, depending on whether local or systemic effects are desired

– Multiple daily peptides (ipamorelin, selank): SC or IN — choose the least stressful route that achieves target bioavailability

– Short half-life CNS peptides (DSIP, Semax): IN preferred to avoid rapid systemic clearance

Research Safety & Ethical Considerations

Responsible peptide research requires rigorous attention to safety protocols, humane treatment of animal subjects, and experimental design that minimizes bias. The following guidelines apply to non-clinical peptide research in animal models.

Dose-Response Determination

Establishing the appropriate dose range is the single most important safety step in peptide research. Unlike small molecule drugs, peptides have unique dose-response characteristics:

– U-shaped dose-response curves are common (BPC-157, GHK-Cu) — higher doses may paradoxically reduce efficacy

– Narrow therapeutic windows in certain peptides (cagrilintide at high doses can cause significant GI effects in animal models)

– Non-linear bioavailability — SC and IP absorption does not scale linearly with concentration; high-concentration solutions may form aggregates at the injection site

Recommended dose-finding protocol:

1. Conduct a literature search for published dose ranges in your specific animal model and species

2. Begin with a 3-dose pilot study at logarithmic spacing (e.g., 0.1×, 1×, 10× of the estimated midpoint dose)

3. Monitor for adverse effects at each dose level for at least 24–48 hours

4. Select the lowest dose that produces a measurable effect for your primary endpoint — this minimizes off-target effects and reduces compound usage

5. Include a vehicle-only group at every dose level

Humane Endpoints in Peptide Research

Peptide research protocols should define humane endpoints prospectively. Common peptide-specific adverse events to monitor include:

Proper Blinding and Randomization

Peptide research is particularly susceptible to observer bias because many endpoints (wound healing scores, behavioral assessments, food intake measurements) require subjective judgment:

– Allocation concealment: Have a colleague not involved in endpoint assessment prepare and label dosing solutions with codes only (no peptide names or doses visible)

– Blinding levels:

– Single-blind: The person administering treatments knows the identity, but the person assessing endpoints does not

– Double-blind: Both administering and assessing personnel are blinded; only the data analyst knows group assignments

– Triple-blind: Add the statistician to the blinded group

– Randomization methods: Use block randomization (block size of 2–4 per treatment group) to ensure balanced group sizes throughout the study. Stratify by body weight if obesity studies introduce baseline weight variability.

– Pre-registration: Register your study protocol (including peptide, dose, route, duration, endpoints, and statistical analysis plan) on a public repository (e.g., Open Science Framework, preclinicaltrials.eu) before beginning data collection.

Negative Controls and Baseline Measurements

Negative controls are not optional — they are the foundation of interpretable peptide research:

– Vehicle control: Must match the test peptide solution in pH, osmolarity, buffer composition, and preservatives. Do not use plain saline if your peptide is reconstituted in bacteriostatic water with benzyl alcohol (the preservative itself can produce biological effects).

– Sham injection control: For studies involving surgical wound healing models (BPC-157, TB-500), include a group that receives the same surgical procedure but only vehicle — to distinguish the surgical impact from peptide effects.

– Naïve control (no injection): Include a group that receives no injections at all. This controls for handling/injection stress, which can elevate corticosterone and confound behavioral, metabolic, and immune endpoints.

Essential baseline measurements before peptide administration:

– Body weight (individual, not cage-grouped)

– Fasting blood glucose (for metabolic studies)

– Baseline blood collection (for biomarker analysis)

– Habituation to handling and injection procedures (3–5 days minimum)

– Acclimation to metabolic cages (24–48 hours if using indirect calorimetry)

Regulatory Compliance Notes

– All vertebrate animal research must be reviewed and approved by an Institutional Animal Care and Use Committee (IACUC) or equivalent ethics board

– Peptide research should follow ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines for publication

– Peptide purity and identity data (HPLC, LC-MS) should be retained with study records as chain-of-custody documentation

– For metabolic research involving weight reduction endpoints, additional monitoring for dehydration and electrolyte imbalance is recommended

– Any peptide from a non-GMP source should be tested for endotoxin levels (LAL assay) before in vivo use; <5 EU/kg is the standard threshold

FAQ

Which research peptide is most studied?

BPC-157 is among the most widely studied research peptides, with hundreds of published studies on its tissue repair and protective effects. Among metabolic peptides, semaglutide has the most extensive research literature.

Can different peptides be used together in research?

Yes, but careful consideration of mechanisms and administration protocols is necessary. Common combination studies include BPC-157 + TB-500 (tissue repair), semaglutide + cagrilintide (metabolic research), and CJC-1295 + Ipamorelin (GH axis research). Researchers should verify compatibility and potential interactions.

How do I choose between semaglutide and tirzepatide for my research?

Semaglutide (GLP-1 agonist alone) is appropriate for research specifically targeting GLP-1 receptor mechanisms. Tirzepatide (dual GIP/GLP-1 agonist) is appropriate when studying combined incretin effects. For weight-focused metabolic research, tirzepatide typically produces greater effects at equivalent doses.

What purity is recommended for in vivo peptide research?

≥98% purity by HPLC is the recommended minimum for in vivo research. Lower purity (95%) may be acceptable for cell culture or in vitro studies. Always request a COA with HPLC trace and LC-MS mass verification before use.

How should I store peptide stock solutions?

Peptide stock solutions should be aliquoted into single-use portions and stored at -20°C. Most peptides are stable for 3–6 months under these conditions. Avoid repeated freeze-thaw cycles. For peptides containing cysteine or methionine, use deoxygenated buffers and minimize light exposure.

Where can I find specific peptide sequences for research?

Most popular research peptide sequences are published in peer-reviewed literature or available in public databases (PubChem, UniProt). For custom peptides, the manufacturer can synthesize any provided sequence with standard quality testing.

What administration route should I use for CNS-targeted peptides?

For CNS-targeted peptides such as Semax, Selank, and DSIP, intranasal (IN) administration is the preferred research route. It bypasses the blood-brain barrier via the olfactory and trigeminal pathways, achieving direct CNS delivery with minimal systemic exposure. SC administration of these peptides is not recommended for CNS studies as they undergo rapid systemic clearance and have limited BBB penetration.

How should I handle peptide aggregation issues?

Peptide aggregation is most common with hydrophobic sequences (like semaglutide at high concentrations) or peptides containing multiple cysteine residues (BPC-157). To minimize aggregation: use freshly prepared solutions, avoid vortexing, maintain recommended pH ranges, and consider adding low concentrations of polysorbate 80 (0.01–0.1%) to the vehicle for hydrophobic peptides.

What is a washout period in peptide combination studies?

A washout period is the time between discontinuing one peptide and starting another (or the same peptide in a crossover design). The minimum washout should be at least 5 half-lives of the peptide. For semaglutide (half-life ~7 days in humans, shorter in rodents), this means approximately 10–14 days in rodent studies. For short-half-life peptides like ipamorelin (~2 hours), 24 hours is typically sufficient.

The Bottom Line

The research peptide landscape spans five major categories with distinct mechanisms, applications, and quality requirements. Choosing the right peptide for a specific research question requires understanding both the biology of the target system and the physicochemical properties of the peptide itself.

Three rules for peptide research success:

1. Match the peptide’s mechanism to your research question — don’t use a metabolic peptide for a tissue repair study

2. Verify quality before use — HPLC + LC-MS COA for every batch, ≥98% for in vivo

3. Respect stability and handling — proper reconstitution and storage directly affect experimental reproducibility

Four additional principles for advanced peptide research programs:

4. Select administration routes based on research goals, not convenience — intranasal for CNS targets, subcutaneous for consistent metabolic studies, intraperitoneal for rapid systemic uptake

5. Never skip dose-range pilot studies — peptide dose-response relationships are often non-linear and can be U-shaped

6. Blinding and randomization are not optional — peptide research is particularly susceptible to observer bias in wound healing, behavioral, and metabolic endpoints

7. Document everything — from peptide batch COA to injection logs to IACUC approvals, thorough record-keeping supports reproducibility and publication

For detailed information on individual peptides, see our specific guides on BPC-157, semaglutide GLP-1 research, tirzepatide dual agonist research, AOD9604, and each of the other peptides listed above.